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Abstract: Two years after the warning issued by the Food and Drug Administration on an 
increased risk of suicide for people taking antiepileptic drugs (AEDs), a number of pharma-
coepidemiologic studies have been published but the scientific community is far from definitive 
answers. The present paper is aimed at reviewing available evidence on the association between 
AEDs and suicidal behavior, discussing major variables involved such as the relationship 
between epilepsy, depression, and suicide and the psychotropic potential of AEDs. All studies 
published so far show a lack of concordance and are constrained by various methodological 
limitations. What seems to be established is that mood disorders represent a frequent comorbid-
ity in epilepsy and suicide is a serious complication more frequently encountered in epilepsy 
rather than in the general population. Moreover, a subgroup of patients appears to be at risk 
of developing treatment-emergent psychiatric adverse effects of AEDs independently of the 
specific mechanism of action of the drug. The prior history of suicide attempt, especially pre-
ceding the onset of the epilepsy, may represent a key element explaining why what is observed 
is independent of the specific mechanism of the drug. In general terms, risks associated with 
stopping, or not even starting, AEDs in epilepsy might well be in excess of the risk of suicide 
in epilepsy, as deaths due to accident and epilepsy itself may predominate. Clinicians need to 
pay attention not only to seizure patterns when choosing the appropriate AED but also to a 
number of different parameters (eg, age, gender, working needs, medical comorbidities, history 
of psychiatric disorders, and suicidality before epilepsy onset) and not the least the mental state 
of the patient. Missing severe complications such as suicidal behavior or delaying its treatment 
may worsen the prognosis of epilepsy.
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Introduction
The question of whether people taking antiepileptic drugs (AEDs) are at increased 
risk of suicidal behavior has been a matter of debate in the scientific community for 
more than 2 years.1–4 In fact, in 2008, the Food and Drug Administration (FDA) issued 
a warning to health care professionals about such increased risk.5 Pharmaceutical 
companies had been previously asked to submit data from placebo controlled trials 
of AEDs, regardless of indication, with at least 30 patients involved. Spontaneously 
reported suicidal behaviors occurring during double-blind trials with an AED (or within 
1 day of stopping) were sought and categorized. Data were provided on the use of 
11 AEDs used for epilepsy (25% patients), psychiatric indications (27% patients), and 
‘other conditions’ (48% patients). In the main analysis, almost 28,000 people taking 
AED and over 16,000 people taking placebo were considered. There were 4 completed 
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suicides altogether, all in people taking AEDs and none in 
those taking placebo. The overall odds ratio (OR) for the 
association between AEDs and suicidal behavior or ideation 
was 1.8 (95% CI 1.24 to 2.66), but it was not statistically 
significantly high for ideation alone [1.45 (95% CI 0.93 
to 2.3)].6 As a result of the analysis, the FDA required that 
all manufacturers of drugs in this class include a warning in 
their labeling and develop a medication guide for patients, 
informing them of the risks of suicidal thoughts or actions. 
The FDA also suggested that the warning language be care-
fully worded and that it mention the risk of not treating the 
underlying condition.7
Different authors have pointed out that the FDA’s concern 
might have been excessive,3,4 and that the risk of stopping 
(or not starting) AEDs, particularly in people with epilepsy, 
would be far greater than this hypothetic small increased 
risk of suicidal behavior.8 Nevertheless, the strictly limited 
data on the subject has led to the publication of a number 
of pharmacoepidemiologic studies during the last year. The 
present paper is aimed at reviewing and discussing emerging 
evidence on the association between AEDs and suicidality, 
taking into account a number of other issues that are essential 
to the understanding of the problem such as comorbidities 
in epilepsy, history of psychiatric disorders and suicidal 
behavior predating the onset of epilepsy, and the psychotropic 
potential of AEDs.
Epilepsy, depression, and suicide: 
what is the role of AEDs?
Mood disorders represent the most frequent psychiatric 
comorbidity in patients with epilepsy and reasons for 
such a close link are both biological and psychosocial.9 
 Community-based studies in unselected sample of patients 
with epilepsy, such as the General Practice study10 and the 
Community Health Survey,11 reported a prevalence rate for 
depressive disorders in the order of 20% to 22%. It is evident 
that this rate is much higher in epilepsy than rates reported 
in the general population – about 12%. Studies from selected 
patient groups, such as tertiary referral centers or from sur-
gery programs, noted an even higher prevalence of depres-
sion, ranging between 30% to 50%.12,13 Such differences 
partially reflect the severity of the seizure disorder. In fact, 
while depression seems to occur in only 4% of seizure-free 
patients, it seems very common, up to 21%, in patients with 
uncontrolled epilepsy,14 suggesting that, indeed, patients 
with epilepsy and continuing seizures are significantly more 
likely to suffer from depression than those in remission. 
Whether this may be due to a biological underpinning or to 
the psychosocial limitations associated with a severe seizure 
disorders or both has not yet been clarified.
A number of publications suggest that not only depres-
sion but also suicide is overrepresented in epilepsy. A meta-
analysis of 12 studies estimated the Standardized Mortality 
Ratio (SMR) for suicide in people with epilepsy as 5.1 
(95% CI 3.9 to 6.6), suggesting that people with epilepsy 
are more than 5 times as likely to commit suicide than the 
general population.15 In addition, the authors found the risk of 
suicide to be high in people with surgically treated epilepsy. 
A more recent, large meta-analysis, found the SMR to be 
3.3 (95% CI 2.8 to 3.7).16 The SMR was again found to be 
increased in people with surgically treated epilepsy. Several 
studies have attempted to establish risk factors for suicide in 
people with epilepsy. In the general population, about 90% 
of people who successfully commit suicide have at least 
one psychiatric disorder at the time.17 Epilepsy is frequently 
associated with psychiatric comorbidity, but it is unlikely that 
the psychiatric comorbidity is the only element responsible 
for the increase in suicides in people with epilepsy. A study 
using data sources from Denmark investigated over 20,000 
people who died from suicide and over 400,000 controls 
(up to 20 for each case) alive on the date of the suicide and 
matched for age and sex.18 Of those who committed suicide, 
almost 500 had epilepsy. Those with epilepsy were more than 
3 times more likely to commit suicide than those without 
epilepsy. More people with epilepsy had psychiatric disease 
(rate ratio 4.3), but the rate ratio of suicide in people with 
epilepsy was still 2 compared with those without epilepsy 
after excluding those with psychiatric disease and adjust-
ing for various factors. Some authors have suggested that 
the rate of suicide is higher in people with temporal lobe 
epilepsy.15 Idiopathic generalized epilepsy has recently been 
studied with both retrospective and prospective methods in 
145 consecutive adults.19 No epilepsy-related factors were 
associated with suicide attempts while all index cases had a 
current psychiatric disorder (mood disorders, neurotic disor-
ders, or personality disorders) and psychosocial events were 
considerably relevant. The risk factors for suicide in epilepsy 
are still far from being elucidated. This relationship is likely 
to be multifactorial in origin with biological, constitutional, 
and psychosocial variables being implicated. At any rate, it 
seems evident that suicide prevention represents a relevant 
issue in epilepsy and careful attention needs to be paid in 
selected cases.
In this context, the role of AEDs may be determinant. In 
fact, drugs still remain the mainstay of epilepsy treatment 
but these compounds have a number of mechanisms of 
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action which are likely to be responsible not only for their 
anti-seizure activity but also for their effect on mood and 
behavior. The psychotropic potential of AEDs is related 
to direct and indirect mechanisms.20 A number of studies 
have suggested that treatment with some AEDs is associ-
ated with the occurrence of symptoms of depression while 
other compounds are probably antidepressants. As far as 
first generation compounds are concerned, authors agree 
that there is a link between barbiturates and depression, 
while carbamazepine probably has beneficial effects on 
mood.21–23 Among second generation AEDs, vigabatrin,24 
tiagabine,25 and topiramate26 have been linked to treatment-
emergent depressive symptoms. In some cases, they were 
associated with a sudden complete control of seizures (the 
forced normalization phenomenon),27 while in others they 
seemed unrelated to this. In most cases, a rapid titration of 
the drug28 in patients with refractory epilepsy, a past history 
of depression,29 and a limbic system dysfunction29 represent 
major determinants.
AEDs and suicidality: what  
is the evidence?
During the last year, a number of retrospective cohort and 
case-control studies have been published, which have tried 
to examine the question raised by the FDA meta-analysis 
using observational study methodology.2,30–36 This section 
of the paper presents methodological considerations and 
critiques of major studies that are summarized in Table 1. 
Studies focused only on patients with bipolar disorders 
have not been included because they are not pertinent to the 
 present discussion.2
A major limitation of most of these studies is the failure 
to adjust for past suicidal behavior. This factor is extremely 
important because it is a highly recurrent phenomenon 
(between 14% and 17% will repeat in 1 year and more than 
30% over 10 years),37,38 and the conditions being studied for 
which AEDs are prescribed are often associated with suicidal 
behavior even before diagnosis.39 Additionally, some AEDs 
are thought to have positive effects on mood and others are 
thought to have negative effects;40 thus prescribing practices 
may be influenced by prior suicidal behavior. In the absence 
of adjustment for prior suicidal behavior, it is not possible to 
determine whether or not AEDs are associated with suicidal 
behavior.
One of the first epidemiological studies to have been 
published was a Danish nationwide register of prescriptions, 
comorbidity, psychiatric diagnoses, and cause of death.31 Two 
different approaches were used, a case-crossover study and T
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a retrospective cohort study; past suicidal behavior was not 
accounted for in these studies. In the case-crossover study, 
cases who committed suicide during a 10-year period during 
which they had also taken AEDs were compared to them-
selves during a control period of 30 days 2 (or 4) months 
before the suicide. This approach is weak as it does not 
account for suicidality during the control period. The retro-
spective cohort study included 169,725 people who started 
taking new AEDs over a 10-year period, and who had not 
been prescribed AEDs in the year prior to the 10-year period. 
Suicide during the first 6 months of exposure to a new AED 
was associated with an increased hazard ratio (compared with 
carbamazepine) for clonazepam, valproate, lamotrigine, phe-
nobarbital, and levetiracetam. Only a minority of the cohort 
was registered as having epilepsy and individuals may have 
restarted AED treatment in response to worsening of underly-
ing psychiatric or pain-related symptoms.  Additionally, past 
suicidality was not assessed. It is interesting that valproate 
appeared to increase the risk of suicide, which was not the 
case in the FDA meta-analysis.
Investigators in the US used Veterans Health Admin-
istration data to assess suicide-related behaviors in people 
with a new prescription for monotherapy AED.32 For each 
person aged 66 years and above with new AED treatment 
who had suicide-related behavior, 12 controls were found, 
matched according to a previous history of suicide-related 
behavior, the year of first AED prescription, and a diagno-
sis of epilepsy. Past suicidality was accounted for over an 
unspecified time period. Compared with gabapentin (used by 
more than 75% of the population), there was a slight increase 
in suicide-related behaviors in those taking the newer AEDs 
(levetiracetam or lamotrigine) but only 7 people in the study 
were taking these drugs and the confidence intervals were 
wide. The strongest predictor for suicide-related behavior 
was a diagnosis of an affective disorder prior to the AED 
prescription. In this study, the FDA’s finding that suicidal 
behavior was more common in those with epilepsy than in 
those using AEDs for other indications was not confirmed.
Another US cohort study using the HealthCore Integrated 
Research Database reported an increased risk of suicidal 
attempts, completed suicide, or violent death in patients tak-
ing gabapentin, lamotrigine, oxcarbazepine, tiagabine, and 
valproate regardless of a specific indication.33 People with 
suicidality in the 6 months before study entry were excluded 
from the analysis. Only 0.3% to 19% of the cohort was taking 
AEDs for epilepsy and the median follow-up was 60 days. 
In a secondary analysis (compared to carbamazepine), 
gabapentin was associated with an increased suicidal risk. 
However, this was not seen in the primary analysis with 
topiramate as the referent where lamotrigine, oxcarbazepine, 
tiagabine, and valproate conferred and increased risk for 
suicide attempt or completion. Like other studies in the 
field, the lack of pre-treatment data on other risk factors for 
suicidality, including suicidality prior to the 6 months before 
study entry represents a major limitation.
A nested case-control study used data from the United 
Kingdom General Practice Research Database (GPRD).34 
Analysis adjusted for history of self harm but not for history 
of suicidal behavior. The authors reported a 3-fold increased 
risk of self harm/suicidal behavior (OR = 3.08; 95% CI 1.22 
to 7.77) in patients taking levetiracetam, tiagabine, topi-
ramate, or vigabatrin, arbitrarily classified by the authors 
themselves as high risk drugs and for this reason analyzed 
as a group. Findings in this study were based on a very small 
number of cases (2 cases per high risk drug).41
Another study adopted two approaches using The Health 
Improvement Network database, a 5.7% representative 
sample of the British General Practice study. They compared 
the incidence of suicide-related events in groups defined by 
epilepsy, depression, and AEDs and conducted a case-control 
study of suicide-related events.30 People with a past suicide 
attempt or with a family history of suicide were excluded, 
making this the cleanest analysis. The incidence of suicide-
related events per 100,000 person-years was 15.0 (95% CI 
14.6 to 15.5) among patients without epilepsy, depression, 
bipolar disorder, or AED treatment, 38.2 (95% CI 26.3 to 
53.7) among patients with epilepsy who did not receive 
AEDs, and 48.2 (95% CI 39.4 to 58.5) among patients with 
epilepsy who received AEDs. For the case-control study, 
5 controls, matched for age, gender, and clinical practice, 
were selected for each case. In adjusted analyses, the odds 
of suicide-related events were not increased by AEDs among 
patients with epilepsy (OR, 0.59; 95% CI 0.35 to 0.98) or 
bipolar disorder (1.13; 95% CI 0.35 to 3.61) but were signifi-
cantly associated among patients with depression (1.65; 95% 
CI 1.24 to 2.19) and among those who did not have epilepsy, 
depression, or bipolar disorder (2.57; 95% CI 1.78 to 3.71). 
One possible explanation for these inconsistent results is 
confounding by indication.
A US study used the PharMetrics medical claims database 
to investigate the risk of suicide attempt in a cohort of patients 
taking gabapentin for various indications  (epilepsy, pain 
disorders, bipolar illness, major depression,  schizophrenia, 
and other psychiatric disorders).35 Overall, there was no 
significant difference in suicide attempt rates in the 1 year 
before versus the 1 year after initiation of  gabapentin. 
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 Pre-prescription  suicide attempt rates were 5 times higher 
in  psychiatric  populations compared with nonpsychiatric; 
 therefore these groups were analyzed separately. No drug 
effect was detected in the nonpsychiatric populations  (epilepsy 
and pain syndromes). Significant reductions in suicide attempt 
rates were seen for bipolar disorder, major depression, or other 
psychiatric  illnesses, presumably because the suicide attempts 
precipitated initiation of pharmacotherapy.
What’s the role of these data  
in clinical practice?
As previously stated there seems to be general agreement 
among authors that risks associated with stopping, or not 
even starting, AEDs in epilepsy might well be in excess of 
the so-called risk of suicidality.1,3 In fact, the risks associ-
ated with not taking AEDs are lack of seizure control and 
the complications which may ensue such as accidents or 
 Sudden Unexplained Death in Epilepsy (SUDEP).6 Data 
from the RANSOM study suggested that nonadherence to 
AEDs can have serious or fatal consequences for patients with 
epilepsy, with a 3-fold increase in mortality risk compared 
with patients who are adherent to drug treatment.42
All studies reviewed in this paper on the relationship 
between AEDs and suicidality show a lack of concordance 
and are affected by a number of limitations,43 firstly, the lack 
of a valid standardized psychiatric assessment for suicide. 
Moreover, data come from sources that have not been devel-
oped to study the questions addressed. It has been argued 
that observational studies of drugs for nonpsychiatric condi-
tions are not suitable for investigating suicide or  suicidality. 
 Observational studies may generate hypotheses but are 
complicated by a number of confounding factors, some of 
which are not assessed. In clinical trials that use adverse 
events as the measure of suicidality, suicidal behavior or 
ideation may not be captured.44 However, clinical trials that 
collect information on suicidality in a standardized fashion 
at selected time intervals would be ideal to answer these 
questions, even if these are secondary analyses.
In our opinion, it has to be acknowledged that tailored 
treatment strategies in epilepsy are mandatory. In particular, 
clinicians need to pay attention not only to seizure patterns 
when choosing the appropriate AED but also to a number of 
different parameters (eg, age, gender, working needs, medical 
comorbidities, and so on) and not the least the mental state 
of the patient. In fact, in agreement with others, we suggest 
that early medical treatment with AEDs could potentially 
reduce the suicide risk of patients with epilepsy because of 
the mood-stabilizing properties of some compounds40 and the 
knowledge that suicide attempt and depression can precede 
the development of epilepsy.39 The prognosis of epilepsy and 
the occurrence of severe complications, including suicide, 
may be made worse by missing important comorbidity and 
by delaying or withholding treatment. These issues may be 
compounded by the lack of input from professionals such as 
psychologists, social workers, and psychiatrists.
Conclusion
More than 2 years after the FDA warning on AEDs and sui-
cidality, the scientific community is still far from a final answer 
to the question. The studies published during the last year gen-
erated inconsistent results, attributable to a number of method-
ological limitations. The FDA will be requiring standardized 
assessment of suicidality at regular intervals during follow-up 
in future AED clinical trials. These data will be useful over 
time in considering whether or not AEDs are associated with 
suicidal behavior. The FDA alert has definitely increased the 
awareness of epileptologists on the issue of psychiatric comor-
bidities in epilepsy, emphasizing the need for standardized 
approaches for prevention and  treatment. Moreover, drug com-
panies are aware that tolerability and safety evaluations during 
drug development need to take into account behavioral effects. 
Although it is likely that the question will remain unanswered, 
this issue has definitely stimulated better tailored treatment 
strategies and a careful attention to patients’ needs.
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